Literature DB >> 3148603

Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue.

Y Matsumura1, M Kimura, T Yamamoto, H Maeda.   

Abstract

Enhanced vascular permeability in tumor tissue has profound pathological consequences in tumor biology. However, details of the mechanism involved are not clear. The present work on tumor vascular permeability has led to the following three findings. (i) Ascitic tumor fluid contained kinin (about 1-40 ng/ml), which is known to enhance vascular permeability and induce pain in vivo. (ii) Kinin is generated via the kallikrein-dependent cascade in the ascitic tumor fluid. By blocking this kinin-generating cascade with Kunitz-type soybean trypsin inhibitor the formation of ascites was suppressed. (iii) Blocking of kinin-degrading enzymes (kininases I and II) by an appropriate kininase inhibitor (e.g., captopril) may result in increased permeability, leading to accumulation of the ascitic fluid. This phenomenon was verified by an about 1.2-1.5 fold increase in leakage of 51Cr-labeled bovine serum albumin into the ascites when kininase inhibitors had been administered orally 30 min before intravenous administration of the bovine serum albumin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3148603      PMCID: PMC5917657          DOI: 10.1111/j.1349-7006.1988.tb01563.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


soybean trypsin inhibitor (Kunitz type unless otherwise specified) carboxypeptidase N inhibitor (see page 1328) enzyme‐linked immunosorbent assay enhanced permeability and retention effect in tumor tissue diethylenetriaminepentaacetic acid a generic name of an antitumor agent which is a derivative of neocarzinostatin conjugated with styrene‐maleic acid copolymer (refs. 6, 7)
  22 in total

1.  Enhancement of vascular permeability upon serratial infection: activation of Hageman factor--kallikrein--kinin cascade.

Authors:  K Matsumoto; T Yamamoto; R Kamata; H Maeda
Journal:  Adv Exp Med Biol       Date:  1986       Impact factor: 2.622

2.  Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report.

Authors:  T Konno; H Maeda; K Iwai; S Tashiro; S Maki; T Morinaga; M Mochinaga; T Hiraoka; I Yokoyama
Journal:  Eur J Cancer Clin Oncol       Date:  1983-08

3.  Medial regression and its functional significance in tumor-supplying host arteries. A morphometric study of hepatic arteries in human livers with hepatocellular carcinoma.

Authors:  M Suzuki; T Takahashi; T Sato
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

4.  A serratial protease causes vascular permeability reaction by activation of the Hageman factor-dependent pathway in guinea pigs.

Authors:  R Kamata; T Yamamoto; K Matsumoto; H Maeda
Journal:  Infect Immun       Date:  1985-06       Impact factor: 3.441

5.  Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.

Authors:  M A Ondetti; B Rubin; D W Cushman
Journal:  Science       Date:  1977-04-22       Impact factor: 47.728

6.  The preparation and labeling of DTPA-coupled albumin.

Authors:  D J Hnatowich; W W Layne; R L Childs
Journal:  Int J Appl Radiat Isot       Date:  1982-05

7.  A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic.

Authors:  H Maeda; J Takeshita; R Kanamaru
Journal:  Int J Pept Protein Res       Date:  1979-08

8.  Pepstatin, an inhibitor of leukokinin formation and ascitic fluid accumulation.

Authors:  L M Greenbaum; P Grebow; M Johnston; A Prakash; G Semente
Journal:  Cancer Res       Date:  1975-03       Impact factor: 12.701

9.  A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines.

Authors:  D R Senger; C A Perruzzi; J Feder; H F Dvorak
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

10.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Authors:  Y Matsumura; H Maeda
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

View more
  31 in total

1.  Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention effect in solid tumors.

Authors:  Jun Fang; Haibo Qin; Hideaki Nakamura; Kenji Tsukigawa; Takashi Shin; Hiroshi Maeda
Journal:  Cancer Sci       Date:  2012-01-16       Impact factor: 6.716

2.  Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions.

Authors:  D Fukumura; F Yuan; M Endo; R K Jain
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

Review 3.  Tumor targeting via EPR: Strategies to enhance patient responses.

Authors:  Susanne K Golombek; Jan-Niklas May; Benjamin Theek; Lia Appold; Natascha Drude; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2018-07-19       Impact factor: 15.470

4.  Passive targeting of nanoparticles to cancer: A comprehensive review of the literature.

Authors:  Remon Bazak; Mohamad Houri; Samar El Achy; Wael Hussein; Tamer Refaat
Journal:  Mol Clin Oncol       Date:  2014-07-23

5.  Degradation pathway of kinins in tumor ascites and inhibition by kininase inhibitors: analysis by HPLC.

Authors:  Y Matsumura; H Maeda; H Kato
Journal:  Agents Actions       Date:  1990-03

6.  Tissue kallikrein and kinin receptor expression in an angiogenic co-culture neuroblastoma model.

Authors:  S Naidoo; D M Raidoo
Journal:  Metab Brain Dis       Date:  2006-07-25       Impact factor: 3.584

Review 7.  Drug delivery and transport to solid tumors.

Authors:  Seong Hoon Jang; M Guillaume Wientjes; Dan Lu; Jessie L S Au
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

Review 8.  A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics.

Authors:  Stephanie D Steichen; Mary Caldorera-Moore; Nicholas A Peppas
Journal:  Eur J Pharm Sci       Date:  2012-12-20       Impact factor: 4.384

Review 9.  Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting.

Authors:  Khaled Greish; Jun Fang; Takao Inutsuka; Akinori Nagamitsu; Hiroshi Maeda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Identification of immunoreactive tissue kallikrein in human ductal breast carcinomas.

Authors:  J Rehbock; P Buchinger; A Hermann; C Figueroa
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.